Hopital Prive Jean Mermoz — Clinical Trial Site

93 Registered trials

49 Currently recruiting

Organisation

Hopital Prive Jean Mermoz

Location

Lyon, France

Identifier

ORG-100041148

Address

55 Avenue Jean Mermoz, 69008, France

Departments

69008
anesthésie-réanimation
Anesthesiology
Chirurgie générale
Chirurgie Générale et Digestive
Digestive Oncology
Gastro entérologie et cancérologie digestive
gastro enterology
GASTRO ENTOROLOGY
Gastro-Entérologie et Cancérologie Digestive
Gastro-enterology
Gastro-enterology and Digestive Oncology
Gastro-Enterology and Medical Oncology
Gastroentérologie et cancérologie digestive
Gastroentérologie et oncologie Digestive
Gastroentérologie et Oncologie Gastro-intestinale
Gastroentérologie et oncologie gastrointestinale
Gastroenterology
Gastroenterology and digestive cancer department
Gastroenterology and Gastrinstestinal Oncology
Gastroenterology and gastrintestinal oncology
Gastroenterology and Gastrintestinal Oncology Department
Gastroenterology and gastrointestinal oncology
Hépato Gastro Entérologie et Oncologie
hépato gastro enterology
hépato gastro enterology/digestive oncology
Hepato_Gastro_Enterology
Hépato-Gastro-Entérologie
Hepato-Gastro-Entérology
hepatogastroenterologie
Hepatogastroenterology Oncology
Institut de Cancérologie
Medical Oncology
Medical Oncology Department
Oncologie
Oncologie Médicale
Oncology
Oncology department
Rhône
service d'oncologie
Service d'oncologie médicale
Service de Cancérologie
Service de Gastro-Entérologie et Cancérologie Digestive
Service de Pneumologie
Service Gastro-entérologie et Cancérologie Digestive

Clinical trials at this site (93)

Search interface

Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with… Recruiting

2024-519048-33-00 resected pancreatic adenocarcinoma 10 2025-11-25
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Squamous cell carcinoma of the esophagus 4 2025-10-06
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
metastatic colorectal cancer Recruiting

2023-504831-42-00 patient with colorectal cancer with hepatic metastasis 5 2025-06-27
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat… Recruiting

2023-507873-16-00 1st line treatment for unresectable metastatic colorect 11 2025-03-04
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Fluoropyrimidine (FP)-naive patients with gastrointesti 4 2025-01-17
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting

2024-516709-22-00 metastatic colorectal cancer carcinoma 10 2024-12-16
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
Linezolid or vancomycin surgical site infection prophylaxis LOVip Recruiting

2023-504986-22-00 surgical antibiotic prophylaxis 5 2024-09-30
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal… Recruiting

2024-514083-31-00 squamous cell anal carcinoma 4 2024-07-26
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08